<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879564</url>
  </required_header>
  <id_info>
    <org_study_id>Si783/2018</org_study_id>
    <nct_id>NCT03879564</nct_id>
  </id_info>
  <brief_title>Ketamine-fentanyl VS Fentanyl for Analgosedation in SICU</brief_title>
  <official_title>Efficacy of Ketamine-fentanyl VS Fentanyl for Analgosedation in Postoperative Ventilated SICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded study to evaluate the analgosedative effect of ketamine
      in a surgical intensive care unit. The patients who will receive continuous fentanyl infusion
      for either pain control or sedation will be recruited in this trial. Fentanyl will be
      titrated with initial loading doses of 20 mcg until the numeral rating scale(NRS) less than 4
      or critical care pain observation tool (CPOT) less than 3 or Richmond agitation sedation
      score (RASS) -2-0. Then the patients will be randomised in to receive saline infusion in
      control group (Group C) or ketamine infusion in ketamine group (Group K). Ketamine will be
      administered with an initial bolus of 0.3 mg/kg followed by a perfusion of1.5 mcg/kg/min
      during the first 48 h. The dose of fentanyl will be protocolized adjusted according to NRS or
      CPOT or RASS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>ketamine and normal saline will be filled in 50-ml syringe and will be administered in the same condition</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>fentanyl consumption</measure>
    <time_frame>48 hours after initial fentanyl infusion</time_frame>
    <description>the amount of fentanyl in microgram/kg in the patients who receive ketamine compare with who receive NSS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>30 days after admitted to ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>30 days after admitted to ICU</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomimetic adverse effects</measure>
    <time_frame>72 hours after admitted to ICU</time_frame>
    <description>incidence of delirium assess by CAM ICU hallucination nightmare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bowel motility</measure>
    <time_frame>72 hours after admitted to ICU</time_frame>
    <description>first pass stool day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular effect</measure>
    <time_frame>72 hours after admitted to ICU</time_frame>
    <description>Number of participants that experience episode of unexplained hypertension (sustained (&gt; 30 min) increase in MAP + 25% from baseline) during ketamine infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular effect</measure>
    <time_frame>72 hours after admitted to ICU</time_frame>
    <description>Number of participants that experience tachyarrhythmia;- Supraventricular/ventricular tachycardia during ketamine infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular effect</measure>
    <time_frame>72 hours after admitted to ICU</time_frame>
    <description>Number of participants that experience atrial fibrillation with rapid ventricular response, rate &gt; 110 bpm during ketamine infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular effect</measure>
    <time_frame>72 hours after admitted to ICU</time_frame>
    <description>Number of participants that experience sinus tachycardia rate &gt;130 bpm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Critically Ill</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% NaCl IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr</description>
    <arm_group_label>ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>NSS IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Older than 18 years.

          -  Need ICU care

          -  Need continuous iv fentanyl as an sedative of analgesia drug

        Exclusion Criteria:

          -  Pregnant women

          -  Known allergy to ketamine

          -  Severe cardiovascular disorders (ejection fraction&lt; 30%, acute myocardial infarction,
             decompensated heart failure, significant tachyarrhythmia)

          -  Acute psychosis

          -  coma patient

          -  receive

          -  Renal insufficiency (creatinine clearance &lt; 30 mL/min)

          -  Unable to assess pain with either NRS or CPOT

          -  Neurosurgery/ CVT patients/ trauma patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karuna Wongtangman, bechelor</last_name>
    <phone>+66813475090</phone>
    <email>karuna.pha@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nuanprae Kitisin</last_name>
    <phone>+66896767706</phone>
    <email>nkowenn@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of medicine Siriraj hospital</name>
      <address>
        <city>Bangkok Noi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karuna Wongtangman</last_name>
      <phone>024197879</phone>
      <email>karuna.pha@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Karuna Wongtangman</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

